Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. - Wikidata - wikimedia - TriplyDB

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

http://www.wikidata.org/entity/Q33994512

about

Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy Multimodality Treatment in Ewing's Sarcoma Family Tumors of the Maxilla and Maxillary Sinus: Review of the Literature UK guidelines for the management of bone sarcomas Management of Ewing sarcoma family of tumors: Current scenario and unmet need Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas.Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.Treatment pathway of bone sarcoma in children, adolescents, and young adults Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.Chemotherapy in Ewing's sarcoma.Pre-chemotherapy preservation of fertility in male patients with high-grade malignant bone and soft tissue tumors.Do patients with ewing's sarcoma continue with sports activities after limb salvage surgery of the lower extremity?Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion.Fertility following treatment of high-grade malignant bone and soft tissue tumors in young adults.Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma Metastatic Ewing's sarcoma/PNET of kidney in 40 year old patient Physeal distraction for joint preservation in malignant metaphyseal bone tumors in children En bloc spondylectomy in malignant tumors of the spine.Askin's tumor: a case report and literature review.The clinical outcomes of extracorporeal irradiated and re-implanted cemented autologous bone graft of femoral diaphysis after tumour resection.Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review.Pharmacotherapy of sarcoma.What Sport Activity Levels Are Achieved in Patients After Resection and Endoprosthetic Reconstruction for a Proximal Femur Bone Sarcoma?Sarcomas gone bad: what to do about recurrent Ewing sarcoma.Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome.Ewing sarcoma: clinical state-of-the-art.Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.The treatment outcome for adult patients with Ewing's sarcoma.The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma.Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.Management and Outcome of Ewing Sarcoma of the Head and Neck.Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).Survival of adolescents with cancer treated at pediatric versus adult oncology treatment centers in France.Outcomes after interdisciplinary management of 7 patients with Askin tumor.Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial.

P2860

Q24186965-1C585B34-F56B-4105-82F7-95FAFC147ADD Q26740437-100F6287-BD77-4FB0-8B03-57691D4013B6 Q26752425-4B4F30A0-E236-4421-A8AD-ED62A4202754 Q28073218-83D8870D-CB72-4880-A49E-49B7A264A177 Q28535586-030020EB-3F07-4102-9826-425402722C5C Q33396263-43442608-32B8-41F8-B150-06FB6314720F Q33403469-2749B5A6-F8E3-4651-ABB7-C27604FE41FF Q33410703-E10BB4D4-8346-410B-A5FC-45B7FD4E9676 Q33835657-9F87324C-EB1F-4BCA-BC84-E2A9EB2E400A Q33839052-BFD8DE15-9DED-438E-B208-9A00B8EFD35D Q34155816-5809C5B8-23F2-49B1-91BA-BCD9CCF68263 Q34164686-83BE2560-1787-46C8-8B42-1C585A5AD64C Q34265818-1A193D7E-D65F-423F-A9B7-8C7944282D01 Q35050301-AED57AC3-AC0D-4F63-92D0-A88B9BD1CFAC Q35131440-00707175-35C5-4808-92E2-49E813A5C669 Q35179978-D8554A92-63FD-476E-AA35-D40362B3BA8E Q35848369-72C631E7-B649-4D6C-9E6B-AB563100CCB0 Q35884342-A0B473C9-57C7-4EB7-AFEE-E7176A84CFA8 Q35946703-72DA0495-EA5A-4FE2-85CA-76E8BE3E02DC Q36542645-403E17C0-CA5B-42BF-A9FE-FF3DC9BEC2E1 Q36565249-399030F1-24B7-4944-A437-1792BD4895A9 Q36721999-61485A75-144E-42DC-B225-A391E6D73FC1 Q36881113-F39881BE-47E7-41C5-A203-63052BB67F40 Q37038352-FDD778FE-617B-4D00-9EEA-8DF008FD3F4F Q37400113-9BF52A25-D137-4C22-A08C-B07EF7FE7FB4 Q37532566-1C8636E6-47DA-4664-9CBC-ED8BE09FF9F3 Q37621255-7421E66B-B4A0-40F7-89D6-367EE21C7009 Q37890995-3E37806C-7A00-4B3F-A728-EA71256E5366 Q37958019-AE9D62FD-542D-416A-BE51-AF673CE37D76 Q37980482-2757E356-1550-4A4E-AAD3-D3316ADE20AE Q38079197-F5DF1286-2A43-4DB5-ADCF-8DD24BD8E063 Q38100720-F81DCDC8-587F-42CE-B463-4EE42F1E3E65 Q38315670-FBE02959-E4AB-4867-9909-637EEF393F9D Q38678098-1E04F110-5899-4F6C-A400-6531A7D5D152 Q38678925-AAC92628-694E-46AC-A9F7-2D9BD7BD7D79 Q39006166-5587A2C3-D7D8-4AE7-A5EC-845D464E174E Q39176628-1E9D80F4-00E0-43A9-949B-DEBD7FC78F7D Q40091463-6DC1574E-32D3-4926-8B6E-9DC84BDB43B1 Q40650204-8166DB94-1FFC-4C7C-A156-E3DEA5228477 Q40806118-713A9993-B300-4980-8DB1-932A4850DCEC

P2860

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

http://www.wikidata.org/entity/Q33994512

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@ast

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@en

type

label

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@ast

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@en

prefLabel

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@ast

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@en

P1433

Q33994512-8A219A1F-E886-4A83-85F7-2AD6C067ED9D

P1476

Q33994512-EB4F330B-7DB7-438B-B135-49E3333D1B9F

P2093

Q33994512-0A95B451-E935-469E-B68D-9376B788C5C7

Q33994512-0E9C9DA7-2CCB-471D-8D12-A507D7006053

Q33994512-2A8E55B6-16A4-4E18-8DF3-CD924E1956D3

Q33994512-45CCEE37-B65C-499E-8E12-A0D0FC060860

Q33994512-48CE8543-57DE-4FF2-9AF5-18DC9A8C2FA4

Q33994512-5DC118BC-CCF1-4F93-B58E-B88DF5105F14

Q33994512-9525E7F9-F0D0-4E57-955C-6ACA031B47FC

Q33994512-D2422AF7-B22E-40AB-918C-4CEC11D84885

Q33994512-DE183950-C06E-49EF-B81D-C218AC190AF5

Q33994512-E054FF12-4CFF-4911-BEAA-A3B2B22AFCDD

P304

Q33994512-F57C8E5E-2558-466F-B9E6-C442382284EA

P31

Q33994512-D0226F7C-BAA9-4007-9423-EE424F2AE3BC

P356

Q33994512-5BC74B57-8EE6-4360-B3A3-BAF4CB3F7B95

P433

Q33994512-56FA994B-3CA3-4175-9325-FB98B78E041B

P478

Q33994512-B99EC31A-84FD-4D14-B26A-2A6270720C9F

P577

Q33994512-51125092-17BA-42AD-B043-818EBA668076

P698

Q33994512-5910EF93-00D6-4985-B02E-BAA22702B03B

P356

P1433

Pediatric Blood & Cancer

P1476

Safety assessment of intensive ...... -E.W.I.N.G. 99 clinical trial.

@en

P2093

Alan Craft

http://www.w3.org/2001/XMLSchema#string

Andreas Zoubek

http://www.w3.org/2001/XMLSchema#string

Christine Juergens

http://www.w3.org/2001/XMLSchema#string

Claire Weston

http://www.w3.org/2001/XMLSchema#string

Herbert Juergens

http://www.w3.org/2001/XMLSchema#string

Ian Lewis

http://www.w3.org/2001/XMLSchema#string

Jean Michon

http://www.w3.org/2001/XMLSchema#string

Jeremy Whelan

http://www.w3.org/2001/XMLSchema#string

Michael Paulussen

http://www.w3.org/2001/XMLSchema#string

Odile Oberlin

http://www.w3.org/2001/XMLSchema#string

P304

22-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.20820

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16572419

http://www.w3.org/2001/XMLSchema#string